Abstract
The N-alkylated imino sugars have inhibitory activity against the first enzyme in the pathway for glucosylating sphingolipid in eukaryotic cells, ceramidespecific glucosyltransferase. A therapeutic approach termed ‘substrate deprivation’ or ‘substrate reduction therapy’ (SRT) aims to reduce biosynthetic capability in the cell to match the reduced lysosomal catalytic activity seen in lysosomal storage disorders. The use of N-alkylated imino sugars to establish this therapeutic strategy is described in cell culture and gene knockout mouse disease models. One imino sugar, N-butyl-DNJ (NB-DNJ) has been in clinical trials for type 1 Gaucher disease and has shown to be an effective therapy for this disorder.
Keywords: lysosomal, glycosidase, glucosyltransferase, glycolipid, inhibitor, substrate reduction therapy
Current Topics in Medicinal Chemistry
Title: Therapeutic Applications of Imino Sugars in Lysosomal Storage Disorders
Volume: 3 Issue: 5
Author(s): Terry D. Butters, Raymond A. Dwek and Frances M. Platt
Affiliation:
Keywords: lysosomal, glycosidase, glucosyltransferase, glycolipid, inhibitor, substrate reduction therapy
Abstract: The N-alkylated imino sugars have inhibitory activity against the first enzyme in the pathway for glucosylating sphingolipid in eukaryotic cells, ceramidespecific glucosyltransferase. A therapeutic approach termed ‘substrate deprivation’ or ‘substrate reduction therapy’ (SRT) aims to reduce biosynthetic capability in the cell to match the reduced lysosomal catalytic activity seen in lysosomal storage disorders. The use of N-alkylated imino sugars to establish this therapeutic strategy is described in cell culture and gene knockout mouse disease models. One imino sugar, N-butyl-DNJ (NB-DNJ) has been in clinical trials for type 1 Gaucher disease and has shown to be an effective therapy for this disorder.
Export Options
About this article
Cite this article as:
Butters D. Terry, Dwek A. Raymond and Platt M. Frances, Therapeutic Applications of Imino Sugars in Lysosomal Storage Disorders, Current Topics in Medicinal Chemistry 2003; 3 (5) . https://dx.doi.org/10.2174/1568026033452483
DOI https://dx.doi.org/10.2174/1568026033452483 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements